Literature DB >> 24317636

Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of SMN2 gene.

Peng Wen Pao1, Keng Boon Wee2, Woon Chee Yee1, Zacharias Aloysius Dwi Pramono3, Zacharias Aloysius Dwipramono3.   

Abstract

Spinal muscular atrophy (SMA) is a fatal autosomal recessive disease caused by survival motor neuron (SMN) protein insufficiency due to SMN1 mutations. Boosting SMN2 expression is a potential therapy for SMA. SMN2 has identical coding sequence as SMN1 except for a silent C-to-T transition at the 6th nucleotide of exon 7, converting a splicing enhancer to a silencer motif. Consequently, most SMN2 transcripts lack exon 7. More than ten putative splicing regulatory elements (SREs) were reported to regulate exon 7 splicing. To investigate the relative strength of each negative SRE in inhibiting exon 7 inclusion, antisense oligonucleotides (AONs) were used to mask each element, and the fold increase of full-length SMN transcripts containing exon 7 were compared. The most potent negative SREs are at intron 7 (in descending order): ISS-N1, 3' splice site of exon 8 (ex8 3'ss) and ISS+100. Dual-targeting AONs were subsequently used to mask two nonadjacent SREs simultaneously. Notably, masking of both ISS-N1 and ex8 3'ss induced the highest fold increase of full-length SMN transcripts and proteins. Therefore, efforts should be directed towards the two elements simultaneously for the development of optimal AONs for SMA therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24317636      PMCID: PMC3982506          DOI: 10.1038/mt.2013.276

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  44 in total

1.  An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN.

Authors:  C L Lorson; E J Androphy
Journal:  Hum Mol Genet       Date:  2000-01-22       Impact factor: 6.150

2.  Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2).

Authors:  Y Hofmann; C L Lorson; S Stamm; E J Androphy; B Wirth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

3.  Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.

Authors:  Markus Feldkötter; Verena Schwarzer; Radu Wirth; Thomas F Wienker; Brunhilde Wirth
Journal:  Am J Hum Genet       Date:  2001-12-21       Impact factor: 11.025

4.  Identification of a cis-acting element for the regulation of SMN exon 7 splicing.

Authors:  Hiroshi Miyajima; Hidenobu Miyaso; Masayo Okumura; Junko Kurisu; Kazunori Imaizumi
Journal:  J Biol Chem       Date:  2002-04-15       Impact factor: 5.157

5.  Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1.

Authors:  Luca Cartegni; Adrian R Krainer
Journal:  Nat Genet       Date:  2002-03-04       Impact factor: 38.330

6.  A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene.

Authors:  Zacharias Aloysius Dwi Pramono; Keng Boon Wee; Jian Li Wang; Yi Jun Chen; Qian Bin Xiong; Poh San Lai; Woon Chee Yee
Journal:  Hum Gene Ther       Date:  2012-07-13       Impact factor: 5.695

7.  Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3' splice site pairing.

Authors:  S R Lim; K J Hertel
Journal:  J Biol Chem       Date:  2001-10-02       Impact factor: 5.157

8.  SRp30c-dependent stimulation of survival motor neuron (SMN) exon 7 inclusion is facilitated by a direct interaction with hTra2 beta 1.

Authors:  Philip J Young; Christine J DiDonato; Diane Hu; Rashmi Kothary; Elliot J Androphy; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2002-03-01       Impact factor: 6.150

9.  An intronic splicing enhancer element in survival motor neuron (SMN) pre-mRNA.

Authors:  Hidenobu Miyaso; Masayo Okumura; Shinichi Kondo; Satoshi Higashide; Hiroshi Miyajima; Kazunori Imaizumi
Journal:  J Biol Chem       Date:  2003-02-25       Impact factor: 5.157

10.  hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1.

Authors:  Yvonne Hofmann; Brunhilde Wirth
Journal:  Hum Mol Genet       Date:  2002-08-15       Impact factor: 6.150

View more
  17 in total

1.  MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis.

Authors:  Cheryl M Koh; Marco Bezzi; Diana H P Low; Wei Xia Ang; Shun Xie Teo; Florence P H Gay; Muthafar Al-Haddawi; Soo Yong Tan; Motomi Osato; Arianna Sabò; Bruno Amati; Keng Boon Wee; Ernesto Guccione
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

Review 2.  Diverse role of survival motor neuron protein.

Authors:  Ravindra N Singh; Matthew D Howell; Eric W Ottesen; Natalia N Singh
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2017-01-15       Impact factor: 4.490

Review 3.  How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy.

Authors:  N N Singh; M D Howell; E J Androphy; R N Singh
Journal:  Gene Ther       Date:  2017-05-09       Impact factor: 5.250

4.  Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates.

Authors:  Kathrin Meyer; Laura Ferraiuolo; Leah Schmelzer; Lyndsey Braun; Vicki McGovern; Shibi Likhite; Olivia Michels; Alessandra Govoni; Julie Fitzgerald; Pablo Morales; Kevin D Foust; Jerry R Mendell; Arthur H M Burghes; Brian K Kaspar
Journal:  Mol Ther       Date:  2014-10-31       Impact factor: 11.454

Review 5.  Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases.

Authors:  Kathleen M Schoch; Timothy M Miller
Journal:  Neuron       Date:  2017-06-21       Impact factor: 17.173

6.  Nuclear magnetic resonance reveals a two hairpin equilibrium near the 3'-splice site of influenza A segment 7 mRNA that can be shifted by oligonucleotides.

Authors:  Andrew D Kauffmann; Scott D Kennedy; Walter N Moss; Elzbieta Kierzek; Ryszard Kierzek; Douglas H Turner
Journal:  RNA       Date:  2022-01-04       Impact factor: 4.942

Review 7.  Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.

Authors:  Natalia N Singh; Brian M Lee; Christine J DiDonato; Ravindra N Singh
Journal:  Future Med Chem       Date:  2015-09-18       Impact factor: 3.808

8.  Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides.

Authors:  Peter Järver; Eman M Zaghloul; Andrey A Arzumanov; Amer F Saleh; Graham McClorey; Suzan M Hammond; Mattias Hällbrink; Ülo Langel; C I Edvard Smith; Matthew J A Wood; Michael J Gait; Samir El Andaloussi
Journal:  Nucleic Acid Ther       Date:  2015-01-16       Impact factor: 5.486

Review 9.  Pluripotent Stem Cell-Based Organoid Technologies for Developing Next-Generation Vision Restoration Therapies of Blindness.

Authors:  Ratnesh K Singh; Francois Binette; Magdalene Seiler; Simon M Petersen-Jones; Igor O Nasonkin
Journal:  J Ocul Pharmacol Ther       Date:  2020-10-14       Impact factor: 2.671

Review 10.  Advanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the Brain.

Authors:  Brandon J Walters; Amber B Azam; Colleen J Gillon; Sheena A Josselyn; Iva B Zovkic
Journal:  Front Genet       Date:  2016-01-12       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.